E

    Elutia Inc. (ELUT)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.86
    -0.02 (-1.81%)

    Market Cap: $38.97M

    Last updated: Aug 31, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(12/25)
    Avg Surprise
    +27.04%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.15 - $-0.15
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.13+13.3%
    60d ago$-0.13+13.3%
    30d ago$-0.13+13.3%
    7d ago$-0.13+13.3%
    Current$-0.15
    Revenue Consensus
    $1M
    Range$1M - $1M
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.18
    Range$-0.18 - $-0.18
    1 analysts
    Revenue Consensus
    $600000
    Range$600000 - $600000
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.18---
    Sep 26EST
    		-$-0.15---
    Jun 26
    		$-0.17$-0.15-13.33%Miss+26.1%
    Mar 26
    		$-0.17$-0.15-13.33%Miss+19.0%
    Dec 25
    		$1.48$-0.12+1333.33%Beat+669.2%
    Sep 25
    		$-0.09$-0.15+40.00%Beat-127.3%
    Jun 25
    		$-0.23$-0.17-35.29%Miss+79.8%
    Mar 25
    		$-0.21$-0.20-5.00%Miss+72.0%
    Dec 24
    		$-0.26$-0.25-4.00%Miss+35.0%
    Sep 24
    		$0.33$-0.44+175.00%Beat+166.0%
    Jun 24
    		$-1.14$-0.33-245.45%Miss-75.4%
    Mar 24
    		$-0.75$-0.41-82.93%Miss-53.1%
    Dec 23
    		$-0.40$-0.28-42.86%Miss-5.3%
    Sep 23
    		$-0.50$-0.55+9.09%Beat+31.5%
    Jun 23
    		$-0.65$-0.29-124.14%Miss+5.8%
    Mar 23
    		$-0.49$-0.57+14.04%Beat+18.3%
    Dec 22
    		$-0.38$-0.66+42.42%Beat+53.7%
    Sep 22
    		$-0.73$-0.66-10.61%Miss+9.9%
    Jun 22
    		$-0.69$-0.55-25.45%Miss-200.0%
    Mar 22
    		$-0.60$-0.62+3.23%Beat-20.0%
    Dec 21
    		$-0.82$-0.82+0.00%Beat-43.9%
    Sep 21
    		$-0.81$-0.61-32.79%Miss+94.9%
    Jun 21
    		$-0.23N/A+58.18%Beat+68.7%
    Mar 21
    		$-0.50$-0.57+12.28%Beat-
    Dec 20
    		$-0.57$-0.57+0.00%Beat-
    Sep 20
    		$-15.79$-3.31-377.04%Miss-
    Jun 20
    		$-0.73$-0.74+0.68%Beat-

    Key Metrics

    Valuation
    P/E Ratio0.82EV/EBITDA-3.33x
    Price/FCF-0.83xFCF Yield-120.45%
    Profitability
    Profit Margin426.90%Operating Margin-243.10%
    ROE0.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio1.77xQuick Ratio1.64x
    Trading Statistics
    Beta0.88Avg Volume59.14K
    52-Week High$2.3852-Week Low$0.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.93
    SMA 20$0.90
    SMA 50$0.93
    SMA 200$0.94
    EMA 10$0.91
    EMA 20$0.91
    EMA 50$0.93
    EMA 200$1.09

    MACD

    Line: -0.00Signal: -0.00Hist: -0.00

    ADX

    ADX: 18.5+DI: 13.6-DI: 26.4

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down52.0
    PSAR$1.05

    Bollinger Bands

    Upper Band$1.02
    Lower Band$0.78
    %B Position2658%(Upper)
    Band Width0.36

    RSI (14-Day)

    Neutral
    43.8

    Momentum Oscillators

    Stoch %K38.5
    Stoch %D56.3
    Williams %R-65.2
    ROC (10d)-11.5%
    Momentum-0.11
    CCI (20d)-47.4
    MFI (14d)44.1

    Volatility Measures

    ATR (14d)$0.07(8.6%)
    StdDev (20d)0.06
    Hist Vol75.6%(High)

    Volume Flow

    VWAP$0.87
    OBV-5.0M
    AD Line-16.1M
    CMF (20d)-0.087

    Volume Metrics

    Avg Vol (20d)60.0K
    Vol Ratio0.9x
    VWMA (20d)$0.90

    Pivot Points

    R3$1.00
    R2$0.97
    R1$0.92
    Pivot Point$0.89
    S1$0.85
    S2$0.82
    S3$0.78

    Advanced Oscillators

    TSI-0.44
    Ultimate Osc45.6
    KST10.43

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$2.43M$3.11M$-3,323,000$3.32M$2.75M$2.95M$-2,180,000$3.66M$6.29M$6.69M$5.88M$6.13M
    Cost of Revenue$980,000$1.31M$-2,551,000$1.47M$1.29M$1.57M$-1,462,000$1.87M$3.49M$3.85M$3.75M$3.29M
    Gross Profit$1.45M$1.80M$-772,000$1.85M$1.45M$1.38M$-718,000$1.79M$2.80M$2.84M$2.12M$2.84M
    Operating Expenses$9.40M$8.15M$3.13M$7.06M$9.82M$8.16M$3.83M$10.97M$11.31M$11.32M$10.63M$10.21M
    R&D$2.53M$1.97M$714,000$1.09M$989,000$871,000$123,000$702,000$1.00M$1.17M$1.38M$557,000
    SG&A$3.45M$4.09M$4.00M$3.52M$3.55M$3.72M$3.99M$4.34M$4.69M$5.06M$3.97M$2.76M
    Operating Income$-7,957,000$-6,348,000$-3,906,000$-5,208,000$-8,365,000$-6,777,000$-4,548,000$-9,175,000$-8,510,000$-8,479,000$-8,507,000$-7,371,000
    Interest Income$35,000$108,000$0$0$491,000$-184,000$0$0$0$0$0$0
    Interest Expense$0$1.48M$0$265,000$0$0$0$131,000$1.27M$1.31M$1.51M$1.45M
    Income Before Tax$-7,638,000$-7,824,000$-1,956,000$-375,000$-7,083,000$-1,879,000$-2,328,000$3.35M$-28,371,000$-17,986,000$-15,227,000$-8,507,000
    Income Tax Expense$8,000$70,000$-11,000$8,000$8,000$8,000$2,000$8,000$-11,000$8,000$-8,000$12,000
    Net Income$-7,646,000$-7,469,000$70.79M$-3,868,000$-9,610,000$-3,933,000$-9,061,000$1.29M$-28,180,000$-17,994,000$-9,314,000$-9,747,000
    EBITDA$-7,324,000$-7,602,000$-3,914,000$672,000$-6,628,000$-774,000$-3,242,000$4.39M$-26,188,000$-15,755,000$-12,769,000$-6,052,000
    EBIT$-7,673,000$-7,932,000$-4,211,000$-110,000$-7,574,000$-1,695,000$-4,105,000$3.48M$-27,104,000$-16,673,000$-13,718,000$-7,059,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ELUT

    News

    ELUT | Elutia Inc. Class A Financials - Revenue Breakdown

    This article provides a financial breakdown for Elutia Inc. Class A Common Stock (ELUT), focusing on revenue, insider trading, institutional holdings, analyst ratings, and smart scores. It also offers details on the company's operations, including its drug-eluting biomatrix products for surgical reconstruction, and segments like Women's Health and Cardiovascular. The platform emphasizes data transparency and offers tools for advanced analysis.

    Quiver Quantitative•8/23/26•
    Neutral

    Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

    Elutia Inc. has completed the sale of its SimpliDerm® human acellular dermal matrix business for up to $11 million, including $8 million upfront. This divestiture provides non-dilutive capital and allows Elutia to concentrate resources on its proprietary drug-eluting biomatrix, NXT-41x, which is designed to address post-operative infections in plastic and reconstructive surgery. The company expects FDA clearance for NXT-41x by mid-2027 and believes it has secured sufficient funding to support its operations through the first full year of commercial launch in 2028.

    Sahm•8/19/26•
    Bullish

    Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results

    Elutia Inc. has secured up to $26 million in capital, without an equity offering, to fund its NXT-41x antibiotic-eluting biomatrix through commercial launch, expected in 2028. An independent survey of plastic surgeons revealed strong demand for NXT-41x, with 96% interested in adoption due to concerns about infection risk with current matrices. The company also reported its Q2 2026 financial results, showing a net loss of $7.6 million, and expects FDA clearance for NXT-41 in Q4 2026 and NXT-41x in H1 2027.

    Sahm•8/14/26•
    Bullish

    Elutia Inc. (ELUT): SilverArc Capital reports 4.9% stake in Class A shares

    SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 2,192,980 shares of Elutia Inc. (ELUT) Class A common stock, representing a 4.9% stake. This disclosure, made via an amended Schedule 13G filing, indicates shared voting and dispositive power over these shares, and clarifies that their holding is 5 percent or less of the class. The filing also provides detailed metrics on their ownership, emphasizing the shared control structure.

    Stock Titan•8/14/26•
    Neutral

    Elutia Inc. (ELUT) stake of 2.19M shares reported by SilverArc

    SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 2,192,980 shares of Elutia Inc. (ELUT) Class A common stock, representing a 4.9% stake. This information was disclosed in a SCHEDULE 13G SEC filing, indicating shared voting and dispositive power over these shares. The filing specifies that this ownership is 5 percent or less of the class and was acquired for investment purposes rather than control.

    Stock Titan•8/11/26•
    Neutral

    Frequently Asked Questions About ELUT

    Does ELUT pay dividends?
    Elutia Inc. (ELUT) does not currently pay a regular dividend.
    What is ELUT's P/E ratio?
    Elutia Inc. has a price-to-earnings (P/E) ratio of 0.82.
    What is ELUT's market cap?
    Elutia Inc. (ELUT) has a market capitalization of $38.97M with a current stock price of $0.86.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In